BioCentury | Apr 4, 2011
Company News

Novalar dental news

...the U.S. for the indication (see BioCentury, July 19, 2010). Further details were not disclosed. Novalar Pharmaceuticals Inc....
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

...Osaka:4508)/Novartis AG (NYSE:NVS; SIX:NOVN) Gilenya fingolimod (FTY720) Relapsing-remitting multiple sclerosis (RRMS) MAA action Early 2011 Novalar Pharmaceuticals Inc./sanofi-aventis...
BioCentury | Jul 19, 2010
Clinical News

OraVerse phentolamine regulatory update

...agencies in the U.K., Germany, Italy, France and Spain accepted for review an MAA from Novalar...
...submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. Novalar...
...license to all European countries. OraVerse is already approved in the U.S. for the indication. Novalar Pharmaceuticals Inc....
BioCentury | Jul 15, 2010
Company News

OraVerse MAA accepted for review

...agencies in the U.K., Germany, Italy, France and Spain accepted for review an MAA from Novalar Pharmaceuticals Inc....
...submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. Novalar...
BioCentury | May 13, 2008
Company News

FDA approves Novalar's OraVerse

...FDA approved an NDA from Novalar (San Diego, Calif.) for OraVerse phentolamine (formerly NV-101 ) to...
...anesthetic. The application was reviewed under section 505(b)(2) of the Food, Drug and Cosmetic Act. Novalar...
BioCentury | Dec 24, 2007
Company News

Novalar management update

Novalar Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Hired: Robert Stefanovich as CFO, formerly interim CFO of Xcorporeal Inc.; and Jeffrey Lord as VP of sales, formerly area VP at Straumann Holding AG 's Straumann...
BioCentury | Nov 5, 2007
Company News

Novalar board of directors update

Novalar Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Appointed: Bob More, partner at Domain Associates, as chairman; Mike Raab, partner at New Enterprise Associates; and John Savarese, managing director at Montreux Equity Partners WIR Staff...
BioCentury | Nov 2, 2007
Financial News

Novalar raises $30 million

...New Enterprise Associates. Existing investors Domain Associates; SR One; and Montreux Equity Partners also participated. Novalar's...
...The company expects to launch NV-101 next year. Domain's Bob More was appointed chairman of Novalar...
BioCentury | Aug 27, 2007
Company News

Novalar board of directors update

Novalar Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Appointed: Steven Semmelmayer, president, chairman and CEO of LED Medical Diagnostics Inc. WIR Staff...
BioCentury | Jul 30, 2007
Company News

Novalar, The Forsyth Institute deal

...acetate (EVA) fiber is in preclinical testing. The institute is eligible for milestones and royalties. Novalar Pharmaceuticals Inc....
Items per page:
1 - 10 of 16
BioCentury | Apr 4, 2011
Company News

Novalar dental news

...the U.S. for the indication (see BioCentury, July 19, 2010). Further details were not disclosed. Novalar Pharmaceuticals Inc....
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

...Osaka:4508)/Novartis AG (NYSE:NVS; SIX:NOVN) Gilenya fingolimod (FTY720) Relapsing-remitting multiple sclerosis (RRMS) MAA action Early 2011 Novalar Pharmaceuticals Inc./sanofi-aventis...
BioCentury | Jul 19, 2010
Clinical News

OraVerse phentolamine regulatory update

...agencies in the U.K., Germany, Italy, France and Spain accepted for review an MAA from Novalar...
...submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. Novalar...
...license to all European countries. OraVerse is already approved in the U.S. for the indication. Novalar Pharmaceuticals Inc....
BioCentury | Jul 15, 2010
Company News

OraVerse MAA accepted for review

...agencies in the U.K., Germany, Italy, France and Spain accepted for review an MAA from Novalar Pharmaceuticals Inc....
...submitted under the EU's decentralized procedure, with the U.K. acting as the reference member state. Novalar...
BioCentury | May 13, 2008
Company News

FDA approves Novalar's OraVerse

...FDA approved an NDA from Novalar (San Diego, Calif.) for OraVerse phentolamine (formerly NV-101 ) to...
...anesthetic. The application was reviewed under section 505(b)(2) of the Food, Drug and Cosmetic Act. Novalar...
BioCentury | Dec 24, 2007
Company News

Novalar management update

Novalar Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Hired: Robert Stefanovich as CFO, formerly interim CFO of Xcorporeal Inc.; and Jeffrey Lord as VP of sales, formerly area VP at Straumann Holding AG 's Straumann...
BioCentury | Nov 5, 2007
Company News

Novalar board of directors update

Novalar Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Appointed: Bob More, partner at Domain Associates, as chairman; Mike Raab, partner at New Enterprise Associates; and John Savarese, managing director at Montreux Equity Partners WIR Staff...
BioCentury | Nov 2, 2007
Financial News

Novalar raises $30 million

...New Enterprise Associates. Existing investors Domain Associates; SR One; and Montreux Equity Partners also participated. Novalar's...
...The company expects to launch NV-101 next year. Domain's Bob More was appointed chairman of Novalar...
BioCentury | Aug 27, 2007
Company News

Novalar board of directors update

Novalar Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Appointed: Steven Semmelmayer, president, chairman and CEO of LED Medical Diagnostics Inc. WIR Staff...
BioCentury | Jul 30, 2007
Company News

Novalar, The Forsyth Institute deal

...acetate (EVA) fiber is in preclinical testing. The institute is eligible for milestones and royalties. Novalar Pharmaceuticals Inc....
Items per page:
1 - 10 of 16